114P Clinical interchangeability of programmed cell death-ligand 1 (PD-L1) immunohistochemistry (IHC) assays for the treatment of first-line (1L) non-small cell lung cancer (NSCLC) with cemiplimab

Abstract

Multiple PD-L1 IHC assays have been developed independently targeting the PD-1/PD-L1 axis. The lack of harmonisation has created undue complexity for clinicians who use PD-L1 tests to guide treatment decisions. In this first-of-its-kind bridging study in 1L NSCLC, we demonstrate clinical agreement of two PD-L1 IHC assays using samples from pts treated with 1L cemiplimab in the phase III EMPOWER-Lung 1 study (NCT03088540).